Skip to main content
SpringerLink
Log in

Weder neuroprotektiver, noch krankheitsmodifizierender Effekt

Dopaminagonist bei Morbus Parkinson

  • journal club
  • Published:
InFo Neurologie & Psychiatrie Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Referenzen

  1. Olanow CW et al. N Engl J Med 2009; 361: 1268–1278

    Article  PubMed  CAS  Google Scholar 

  2. Ahlskog JE, Uitti RJ. Neurology 2010; 74: 1143–1148

    Article  PubMed  CAS  Google Scholar 

Literatur

  • Schapira AH, McDermott MP, Barone P et al. Pramipexole in patients with early Parkinson’s disease (PROUD): a randomised delayed-start trial. Lancet Neurol 2013; 12: 747–755

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Universitätsklinikum, Schleswig-Holstein, Deutschland

    Günther Deuschl (Direktor der klinik für Neurologie)

Authors
  1. Günther Deuschl
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Günther Deuschl.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Deuschl, G. Weder neuroprotektiver, noch krankheitsmodifizierender Effekt. InFo Neurologie 15, 25 (2013). https://doi.org/10.1007/s15005-013-0600-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15005-013-0600-x

Search

Navigation